pleconaril has been researched along with Common Cold in 11 studies
WIN 63843: structure given in first source
Common Cold: A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pleconaril treatment was associated with a more rapid loss of culturable virus." | 6.71 | Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. ( Barone, LR; Collett, MS; Demenczuk, TM; Hayden, FG; McKinlay, MA; Pevear, DC, 2005) |
| "We tested the in vitro activity of pleconaril and AG7088 against five numbered human rhinovirus (HRV) serotypes and 46 clinical HRV isolates of undefined serotype recovered from patients with common colds." | 3.70 | In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. ( Crump, CE; Hayden, FG; Kaiser, L, 2000) |
| "Oral pleconaril treatment was studied in 2 parallel randomized, double-blind, placebo-controlled trials." | 2.71 | Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. ( Coats, TL; Collett, M; Cooper, EC; Hayden, FG; Herrington, DT; Hudson, S; Kim, K; Liu, S; McKinlay, M; Pevear, DC; Villano, SA, 2003) |
| "Pleconaril treatment was associated with a more rapid loss of culturable virus." | 2.71 | Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. ( Barone, LR; Collett, MS; Demenczuk, TM; Hayden, FG; McKinlay, MA; Pevear, DC, 2005) |
| "Recent attempts to develop antiviral treatments for the common cold represent a substantial advance over previous efforts." | 2.41 | The treatment of rhinovirus infections: progress and potential. ( Turner, RB, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mello, C | 1 |
| Aguayo, E | 1 |
| Rodriguez, M | 1 |
| Lee, G | 1 |
| Jordan, R | 1 |
| Cihlar, T | 1 |
| Birkus, G | 1 |
| Choi, HJ | 1 |
| Song, JH | 1 |
| Lim, CH | 1 |
| Baek, SH | 1 |
| Kwon, DH | 1 |
| Greenwood, V | 1 |
| Hayden, FG | 4 |
| Herrington, DT | 1 |
| Coats, TL | 1 |
| Kim, K | 1 |
| Cooper, EC | 1 |
| Villano, SA | 1 |
| Liu, S | 1 |
| Hudson, S | 1 |
| Pevear, DC | 2 |
| Collett, M | 1 |
| McKinlay, M | 1 |
| Fleischer, R | 1 |
| Laessig, K | 1 |
| Demenczuk, TM | 1 |
| Barone, LR | 1 |
| McKinlay, MA | 1 |
| Collett, MS | 1 |
| Kaiser, L | 1 |
| Crump, CE | 1 |
| Turner, RB | 1 |
| Senior, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biomarkers and Clinical Characteristics That Identify the Risk of an Exacerbation Following Viral Upper Respiratory Tract Infections in COPD Patients[NCT01376830] | 35 participants (Actual) | Observational | 2011-06-30 | Completed | |||
| A Phase 1 Study to Confirm the Single- and Multiple-dose Pharmacokinetics and to Evaluate Food Effect of Vapendavir in Healthy Participants and Participants With COPD[NCT05962645] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-05-19 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pleconaril and Common Cold
| Article | Year |
|---|---|
Update on influenza and rhinovirus infections.
Topics: Acetamides; Amines; Antiviral Agents; Common Cold; Guanidines; Humans; Influenza, Human; Intercellul | 1999 |
The treatment of rhinovirus infections: progress and potential.
Topics: 3C Viral Proteases; Antiviral Agents; Clinical Trials as Topic; Combined Modality Therapy; Common Co | 2001 |
2 trials available for pleconaril and Common Cold
| Article | Year |
|---|---|
Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials.
Topics: Administration, Oral; Adult; Antiviral Agents; Common Cold; Diarrhea; Double-Blind Method; Female; H | 2003 |
Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses.
Topics: Antiviral Agents; Common Cold; Double-Blind Method; Drug Resistance, Bacterial; Humans; Oxadiazoles; | 2005 |
7 other studies available for pleconaril and Common Cold
| Article | Year |
|---|---|
Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C.
Topics: Antiviral Agents; Common Cold; Dose-Response Relationship, Drug; HeLa Cells; Humans; In Vitro Techni | 2014 |
Anti-human rhinovirus activity of raoulic acid from Raoulia australis.
Topics: Antiviral Agents; Asteraceae; Common Cold; Humans; Microbial Sensitivity Tests; Oxadiazoles; Oxazole | 2010 |
Curing the common cold.
Topics: Antiviral Agents; Common Cold; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oxadiazole | 2011 |
Cold comfort.
Topics: Antiviral Agents; Common Cold; Drug Approval; Humans; Oxadiazoles; Oxazoles; United States; United S | 2002 |
Safety and efficacy evaluation of pleconaril for treatment of the common cold.
Topics: Adult; Antiviral Agents; Common Cold; Controlled Clinical Trials as Topic; Drug Resistance, Viral; E | 2003 |
In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses.
Topics: Antiviral Agents; Cell Survival; Cells, Cultured; Common Cold; Humans; Isoxazoles; Oxadiazoles; Oxaz | 2000 |
FDA panel rejects common cold treatment.
Topics: Antiviral Agents; Common Cold; Drug Approval; Female; Humans; Oxadiazoles; Oxazoles; United States; | 2002 |